Biotech

All Articles

Zephyrm looks for Hong Kong IPO to finance period 3 cell therapy trials

.Zephyrm Bioscience is gusting towards the Hong Kong stock market, declaring (PDF) for an IPO to mon...

Frazier Lifestyle Sciences collects $630M for little, mid-cap biotechs

.Frazier Life Sciences has actually sourced an additionally $630 thousand for its own fund focused o...

GigaGen gathers around $135M BARDA bucks to beat botox

.Antibody aficionado GigaGen, a subsidiary of Spanish biopharma Grifols, is actually increase its ow...

GPCR firm Septerna declare IPO on durability of preclinical information

.Septerna is about to learn just how a biotech without "any sort of meaningful clinical data" fares ...

Kurma finalizes first $154M payload for most significant biotech fund as yet

.European VC firm Kurma Partners has actually introduced its own most current biotech fund, with 140...

Prothena ensures one director while yet another leaves behind-- Chutes &amp Ladders

.Welcome to today's Chutes &amp Ladders, our roundup of significant management hirings, firings as w...

Editas cashes in on Tip Cas9 licensing civil rights for $57M

.Against the backdrop of a Cas9 patent fight that refuses to die, Editas Medicine is cashing in a po...

Ultragenyx changes gene treatment dosing to dial up effectiveness

.A minority of people taking Ultragenyx Pharmaceutical's Wilson health condition genetics treatment ...

Biopharma layoff cost stabilizes in Q3: Intense Biotech analysis

.As summer months heat counts on cool winds, really hopes that this year would bring extensive busin...

J &amp J goes down period 2 dengue candidate in most current switch coming from vaccines

.Johnson &amp Johnson's deprioritization of its own infectious ailment pipeline has claimed one more...